頁籤選單縮合
題名 | 口服抗憂鬱藥Agomelatine=Oral Antidepressant--Agomelatine |
---|---|
作者 | 吳芝瑩; 梁高誌; Wu, Chih-yin; Liang, Kao-chih; |
期刊 | 藥學雜誌 |
出版日期 | 20130900 |
卷期 | 29:3=116 2013.09[民102.09] |
頁次 | 頁43-47 |
分類號 | 418.214 |
語文 | chi |
關鍵詞 | 單胺氧化酶抑制劑; 三環類抗憂鬱劑; 選擇性血清素抑制劑; 血清素及正腎上腺素再吸收抑制劑; 褪黑激素受體; 色氨酸受體; |
中文摘要 | 現代人的生活壓力愈來愈大,根據 WHO 的統計,全球有超過三百五十萬人口患有憂鬱症,最壞的狀況下,憂鬱症會導致自殺。不幸的是,每年有將近一百萬人選擇自殺,他們其中有相當大的比例患有憂鬱症;而治療憂鬱症來說,除給予憂鬱症患者適當的照顧、心理社會上的支持,也要加上適當的藥物治療。自從1950年代發現結核病藥品 isoniazid 可以治療憂鬱症後,數年間,許多抗憂鬱藥逐漸被發現。包括單胺氧化酶抑制劑 (monoamine oxidase inhibitors; MAOIs)、三環類抗憂鬱劑 (tricyclic antidepressants; TCAs),以及近期的選擇性血清素抑制劑 (selective serotonin reuptake inhibitors; SSRIs) 和血清素及正腎上腺素再吸收抑制劑 (serotonin-norepinephrine reuptake inhibitors, SNRIs),使得在憂鬱症治療上有許多藥可做為選擇。一直以來,這些抗憂鬱藥的服用容易導致副作用,讓許多服用的人感到痛苦不堪,難以擺脫藥品依賴的狀況。Agomelatine 是第一個合成的褪黑激素 (melantonin) 類似物抗憂鬱劑,可活化 MT1、MT2這兩個褪黑激素的受體 (melatonergic receptor; MT) 以及抑制5HT2C 色氨酸受體 (serotonin receptor) 的活化,這樣的作用除了對於憂鬱症能夠專一性的治療,間接改善治療時副作用的發生,也一併改善了睡眠狀況。 |
英文摘要 | Along with inereasing pressures of modern life, according to WHO statistics, more than 3.5 million people worldwide are suffering from depression. The worst depression can lead to suicide. Unfortunately, nearly 1 million people suicide every year, the relatively large proportion of them are suffering from depression. For the treatment of depression, in addition to give proper care, and psychosocial support, it meeds proper medication as well. Since tuberculosis drug isoniazid useful in depression-treatment in the 1950s, many antidepressant drugs have been gradually discovered in a few years. Including monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), selective serotonin inhibitors (selective serotonin reuptake inhibitors; SSRIs) and serotonin and positive norepinephrine reuptake inhibitors (serotonin-norepinephrine reuptake inhibitors, SNRIs) found recently, so there are many drugs can be selected to treat depression. Until now, these antidepressants are still easily lead to side effects, so many people taking painful and difficult to get rid of the status of drug dependence. Agomelatine is the first synthetic melatonin analogs antidepressant which can activate melatonin receptor MT1、MT2, and inhibit serotonin receptor 5HT2C, such mechanism either provide specific therapy to depression, or indirectly improve the occurrence of side effects and the condition of sleep. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。